Antimicrobial activity of linezolid combined with minocycline against vancomycin-resistant Enterococci

Chinese Medical Journal

Volumn 126, Issue 14, 2013, Pages 2670-2675

  Wu, Jing ^a   Jiang, Tian Tong ^b   Su, Jian Rong ^c   Li, Li ^c  

^a First Hospital of Fangshan District   (China)

^b JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Enterococcus; Linezolid; Minocycline; Mutation

Indexed keywords

LINEZOLID; MINOCYCLINE;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL MUTATION; BROTH DILUTION; COMPARATIVE STUDY; CONTROLLED STUDY; GROWTH CURVE; MINIMUM INHIBITORY CONCENTRATION; MUTATION RATE; NONHUMAN; OPTICAL DENSITY; POLYMERASE CHAIN REACTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DRUG THERAPY, COMBINATION; ENTEROCOCCUS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MUTATION; OXAZOLIDINONES; VANCOMYCIN RESISTANCE;

EID: 84880459073     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20122630     Document Type: Article

References (27)

1. Uttley AH, George RC, Naidoo J, Woodford N, Johnson AP, Collins CH, et al. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect 1989; 103: 173-181.
2. Bonten MJ, Willems R, Weinstein RA. Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis 2001; 1: 314-325.
3. Courvalin P. Vancomycin resistance in Gram-positive cocci. Clin Infect Dis 2006; 42: S25-S34.
4. Boyd DA, Willey BM, Fawcett D, Gillani N, Mulvey MR. Molecular characterization of Enterococcus faecalis N06-0364 with low-level vancomycin resistance harboring a novel D-Ala-D-Ser gene cluster, vanL. Antimicrob Agents Chemother 2008; 52: 2667-2672.
5. McKessar SJ, Berry AM, Bell JM, Turnidge JD, Paton JC. Genetic characterization of vanG, a novel vancomycin resistance locus of Enterococcus faecalis. Antimicrob Agents Chemother 2000; 44: 3224-3228.
6. Xu X, Lin D, Yan G, Ye X, Wu S, Guo Y, et al. vanM, a new glycopeptide resistance gene cluster found in Enterococcus faecium. Antimicrob Agents Chemother 2010; 54: 4643-4647.
7. Lebreton F, Depardieu F, Bourdon N, Fines-Guyon M, Berger P, Camiade S, et al. D-Ala-D-Ser VanN-type transferable vancomycin resistance in Enterococcus faecium. Antimicrob Agents Chemother 2011; 55: 4606-4612.
8. Cooper MA, Fiorini MT, Abell C, Williams DH. Binding of vancomycin groupantibiotics to D-alanine and D-lactate presenting self-assembled monolayers. Bioorg Med Chem 2000; 8: 2609-2616.
9. Farrell DJ, Mendes RE, Ross JE, Jones RN. Linezolid surveillance program results for 2008 (LEADER program for 2008). Diagn Microbiol Infect Dis 2009; 65: 392-403.
10. Auckland C, Teare L, Cooke F, Kaufmann ME, Warner M, Jones G, et al. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J Antimicrob Chemother 2002; 50: 743-746.
11. Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6414 clinical isolates from 56 medical centers in the United States. Antimicrob Agents Chemother 2011; 55: 3684-3690.
12. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357: 1179.
13. Marshall SH, Donskey CJ, Hutton-Thomas R, Salata RA, Rice LB. Gene dosage and linezolid resistance in enterococcus faeciumand enterococcus faecalis. Antimicrob Agents and Chemother 2002; 46: 3334-3336.
14. Ruggero KA, Schroeder LK, Schreckenberger PC, Mankin AS, Quinn JP. Nosocomial superinfections due to linezolid resistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs. Diagn Microbiol Infect Dis 2003; 47: 511-513.
15. Kloss P, Xiong L, Shinabarger DL, Mankin AS. Resistance mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol 1999; 294: 93-101.
16. Diaz L, Kiratisin P, Mendes RE, Panesso D, Singh KV, Arias CA. Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis. Antimicrob Agents Chemother 2012; 56: 3917-3922.
17. Cattoir V, Leclercq R. Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce? J Antimicrob Chemother 2013; 68: 731-742.
18. Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 2003; 52: 11-17.
19. Boak LM, Li J, Rayner CR, Nation RL. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro mode. Antimicrob Agents Chemother 2007; 51: 1287-1292.
20. Roberts MC. Update on acquired tetracycline resistance genes. FEMS Microbiol Lett 2005; 245: 195-203.
21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. M100-S20 (Accessed January 01, 2012 at http://www.techstreet.com/products/1662846).
22. Principe L, D'Arezzo S, Capone A, Petrosillo N, Visca P. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob 2009; 8: 18.
23. Eliopoulos GM, Wennersten CB. Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci. Antimicrob Agents Chemother 2002; 46: 1319-1324.
24. Blondeau JM. New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach. Vet Dermatol 2009; 20: 383-396.
25. Qi C, Zheng X, Obias A, Scheetz MH, Malczynski M, Warren JR. Comparison of testing methods for detection of decreased linezolid susceptibility due to G2576T mutation of the 23S rRNA gene in enterococcus faecium and enterococcus faecalis. J Clin Microbiol 2006; 44: 1098-1100.
26. Manfredi R. Update on the appropriate use of linezolid in clinical practice. Ther Clin Risk Manag 2006; 2: 455-464.
27. Kenneth N. Agwuh and alasdair macgowan. Pharmacokinetics and pharmacodynamics of the tetracyclines. J Antimicrob Chemother 2006; 58: 256-265.